证券代码：300404 证券简称：博济医药 广州博济医药生物技术股份有限公司 投资者关系活动记录表 | --- | --- | |--------------|----------------------------| | | | | | □ 特定对象调研 □分析师会议 | | 投资者关系活 | □ 媒体采访 □业绩说明会 | | 动类别 | □ 新闻发布会 □路演活动 | | | □ 现场参观 | 1 | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300404 证券简称：博济医药 1 广州博济医药生物技术股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | □ 特定对象调研 □分析师会议 | | 投资者关系活 | □ 媒体采访□业绩说明会 | | 动类别 | □新闻发布会□路演活动 | | | ■ ...

证券代码：300404 证券简称：博济医药 广州博济医药生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------|-------------------------------------------------------------------| | | □ 特定对象调研 | □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | | □新闻发布会 □路演活动 | | | ■ 现场参观 | | | | □ | 其他（投资者电话交流会） | | | | 中信证券、广发证券、天风证券、上信资管、银河投资、广州金控、 | | | | 灏浚投资、常州投资集团、久银投资、瑞瀚资管、恒兆亿基金、长城 | | 参与单位名称 及人员姓名 | | 财富、广东圆澄基金、华银天夏基金、广东瑞天、恒健投资、新兴产 | | | | 业投资基金、金融控股集团、纽富斯资管、中融国际信托、泉达投 | | | | 资、招商财富资管、财通基金 | | 时间 | 2020 年 11 月 ...

博济医药科技股份有限公司 2022 年第三季度报告 3.第三季度报告是否经过审计 □是 否 1 博济医药科技股份有限公司 2022 年第三季度报告 一、主要财务数据 证券代码：300404 证券简称：博济医药 公告编号：2022-076 博济医药科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 103,364,118.12 | 9.93% | 27 ...

Financial Performance - The company achieved total operating revenue of ¥175,064,487.73, an increase of 44.96% compared to the same period last year[39]. - Net profit attributable to shareholders was ¥14,876,925.54, reflecting a growth of 5.68% year-on-year[39]. - The net profit after deducting non-recurring gains and losses decreased by 48.54% to ¥3,792,695.91[4]. - The net cash flow from operating activities increased by 92.24% to ¥20,669,699.97[4]. - Clinical research services revenue reached ¥114,848,813.14, a year-on-year increase of 70.40%, with new contracts amounting to ¥265 million, up 40.95%[40]. - Preclinical research services generated revenue of ¥30,173,123.29, a decrease of 4.24%, while new contracts totaled ¥71,125,300, reflecting a growth of 104.5%[41]. - Other consulting services revenue was ¥20,017,967.82, an increase of 8.29%, with new contracts amounting to ¥37,518,100, up 81.13%[42]. - The company's operating revenue for the reporting period reached ¥175,064,487.73, representing a year-on-year increase of 44.96% due to steady project progress[59]. - Operating costs increased by 60.25% to ¥105,485,076.30, primarily driven by the rise in operating revenue[59]. - Research and development expenses rose by 51.69% to ¥18,721,687.34, reflecting the company's increased investment in R&D and the hiring of additional personnel[59]. - The gross margin for clinical research services decreased by 4.18% to 32.37%, mainly due to rising labor costs during the reporting period[62]. - The total profit for the first half of 2022 was CNY 16,773,484.54, compared to CNY 17,782,431.69 in the same period of 2021, indicating a decrease of 5.7%[185]. - The company reported a basic earnings per share of CNY 0.0406, slightly down from CNY 0.0424 in the previous year[186]. - The total comprehensive income for the first half of 2022 was CNY 17,529,192.22, compared to CNY 16,444,393.82 in the same period of 2021, showing an increase of 6.6%[186]. - The company reported a net profit of CNY 620.2 million from its subsidiary Guangzhou Boji, contributing over 10% to the overall net profit[91]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,181,416,435.83, up 3.80% from the end of the previous year[4]. - Cash and cash equivalents at the end of the reporting period amounted to ¥348,074,200, representing 29.46% of total assets, a decrease of 4.32% compared to the previous year[66]. - Accounts receivable stood at ¥71,504,036.5, accounting for 6.05% of total assets, a slight decrease of 0.25% year-on-year[66]. - Contract assets increased to ¥38,775,518.9, which is 3.28% of total assets, reflecting a growth of 0.58% from the previous year[66]. - Inventory reached ¥165,528,179, making up 14.01% of total assets, an increase of 0.98% compared to last year[66]. - Long-term equity investments rose to ¥4,615,096.59, representing 0.39% of total assets, up by 0.28% year-on-year[66]. - The company's total assets as of June 30, 2022, amounted to ¥1,181,416,435.83, compared to ¥1,138,209,210.53 at the beginning of the year, reflecting a growth of 3.8%[179]. - Current liabilities decreased to ¥259,298,904.19 from ¥270,844,957.87, a reduction of 4.5%[179]. - The company's equity attributable to shareholders increased to ¥838,244,367.91, up from ¥813,994,073.02, representing a growth of 3.0%[179]. - The company's non-current liabilities totaled ¥51,254,920.03, significantly higher than ¥20,986,445.90 at the start of the year, indicating a rise of 144.5%[179]. Investments and Financing - Investment activities generated a net cash outflow of -¥72,473,614.29, a significant increase of 231.37% compared to the previous year, primarily due to payments for equipment and project investments[59]. - The company reported a decrease of 95.43% in cash flow from financing activities, totaling ¥13,808,920.81, due to the previous year's fundraising activities[59]. - The company reported a total guarantee amount of 17,000 million RMB during the reporting period, with an approved guarantee limit of 30,000 million RMB[137]. - The actual guarantee amount accounted for 20.28% of the company's net assets[138]. - The company increased its financing credit limit from 300 million RMB to 500 million RMB, and the financing guarantee limit for subsidiaries from 200 million RMB to 300 million RMB[141]. - The company has committed to using up to 100 million yuan of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months[81]. - The total amount of raised funds was ¥33,641.67 million, with ¥1,125.62 million invested during the reporting period[76]. - Cumulative investment of raised funds reached ¥14,551.65 million, with a remaining balance of ¥19,503.52 million in the dedicated account[77]. Corporate Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[3]. - The company emphasizes compliance with national drug supervision regulations and quality management standards[16]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[118]. - There were no violations regarding external guarantees during the reporting period[119]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[112]. - The company emphasizes the protection of shareholder rights and adheres to legal regulations for corporate governance[113]. Market and Industry Outlook - The global CRO market is projected to reach $76.1 billion by 2023, with a compound annual growth rate of 10.4% from 2018 to 2023[35]. - The Chinese CRO market is expected to grow from $6.8 billion in 2019 to $22.2 billion by 2024, with a compound annual growth rate of approximately 26.5%[36]. - The company has identified risks related to policy changes in the new drug approval process, which could impact revenue and R&D investments[92]. - The company faces risks from long contract execution periods in new drug development, which may lead to delays and potential cost overruns[93]. - The company is exposed to market competition risks due to the rapid growth of domestic CRO companies, necessitating enhanced marketing and service levels[94]. - The company plans to leverage its full industry chain service advantages to improve core competitiveness and strategic planning[94]. Stock Options and Incentives - The company plans to grant 2.7 million stock options at an exercise price of 12.27 CNY per share under the 2022 stock option incentive plan[107]. - The company has adjusted the total number of stock options under the 2020 incentive plan from 1,823,260 to 2,552,564, with a new exercise price of 9.56 CNY per share[106]. - The company has canceled 82,900 stock options from the 2020 incentive plan due to the departure of four incentive targets[105]. - The stock option incentive plan was adjusted from 87 participants to 86, with a total of 2,699,000 options granted[108]. - The total number of unexercised stock options increased from 2,697,000 to 3,775,800 following the completion of the 2021 annual equity distribution[109]. Legal Matters - The company is currently involved in two major lawsuits, one with an amount of 259.95 million RMB and another with 148 million RMB, both of which are not expected to significantly impact operations[122]. - The first lawsuit was dismissed by the Guangzhou Intellectual Property Court, rejecting all claims from the plaintiff[122]. - The second lawsuit is in the second instance stage, awaiting a decision, but is also not expected to have a major impact on the company's operations[122]. Employee and Management - Employee benefits include competitive salaries and a stock ownership plan to share company growth[113]. - The company has strengthened internal management and integration efforts to mitigate management risks associated with business expansion[95]. - The company has introduced specialized management talent to improve operational efficiency[95]. - The company has faced challenges in new business development due to insufficient market expansion capabilities and project experience[95].

博济医药科技股份有限公司 2022 年第一季度报告全文 证券代码：300404 证券简称：博济医药 公告编号：2022-038 博济医药科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 74,184,304.67 | 55,245,275.36 | 34.28% | | 归属于上市公司股东的净利润（元） | 12,461,872.32 | 7,369,156 ...

Financial Performance - The company's operating revenue for 2021 was RMB 324,202,622.53, representing a 24.47% increase compared to RMB 260,468,434.47 in 2020[19]. - The net profit attributable to shareholders in 2021 was RMB 38,882,189.38, a significant increase of 128.87% from RMB 16,988,641.81 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 25,214,668.12, up 155.84% from RMB 9,855,541.21 in 2020[19]. - The company's total assets increased by 51.84% to RMB 1,138,209,210.53 at the end of 2021, compared to RMB 749,631,868.84 at the end of 2020[19]. - The net assets attributable to shareholders rose by 83.23% to RMB 813,994,073.02 at the end of 2021, up from RMB 444,239,449.04 in 2020[19]. - The basic earnings per share for 2021 was RMB 0.1594, reflecting a 112.25% increase from RMB 0.0751 in 2020[19]. - The diluted earnings per share was RMB 0.1588, also up 112.02% from RMB 0.0749 in the previous year[19]. - The net cash flow from operating activities decreased by 68.99% to RMB 30,101,746.56 in 2021, down from RMB 97,067,618.03 in 2020[19]. - The company reported a weighted average return on equity of 6.26% for 2021, an increase of 2.32 percentage points from 3.94% in 2020[19]. Business Strategy and Expansion - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[6]. - The company aims to enhance its core competitiveness through strategic planning and leveraging its full industry chain service advantages[5]. - The company is focusing on developing innovative drug clinical services and preclinical services to mitigate risks associated with market competition[4]. - The company is committed to strengthening internal management and integrating professional management talent to improve operational efficiency[6]. - The company is focused on providing comprehensive "one-stop" CRO services, including preclinical research, clinical research, and CDMO services[36]. - The company plans to strengthen its clinical research services, particularly in liver disease, oncology, and respiratory fields, while expanding into cell and gene therapy research[110]. - The company aims to develop a comprehensive new drug research platform integrating drug research, clinical trials, and production, enhancing its competitive edge in the CRO industry[108]. - The company is actively seeking acquisition targets in niche markets to achieve rapid expansion[112]. Research and Development - The company has established six major R&D service platforms, enhancing its capabilities in traditional Chinese medicine and chemical drug research[56]. - The company has received multiple government grants for its R&D platforms, indicating strong support for its innovation efforts[57]. - The company has developed over 30 drug research projects, obtaining 3 production licenses and 5 clinical research approvals[145]. - The company has filed nearly 20 patents and published over 30 academic articles related to drug development[145]. - The company is advancing its KHK target compound screening system, which is expected to meet the demand for innovative fatty liver treatments[78]. - The company has established partnerships with various academic and research institutions to enhance innovation[145]. Market and Competition - The CRO market is projected to reach USD 64.58 billion by 2021, with a compound annual growth rate (CAGR) of 12.8% from 2016 to 2021[30]. - The Chinese CRO market is expected to grow from USD 6.8 billion in 2019 to USD 22.2 billion by 2024, with a CAGR of approximately 26.5%[31]. - The company acknowledges the increasing market competition in the CRO industry, necessitating higher marketing and service standards[5]. Governance and Compliance - The company has established and improved its governance structure in compliance with relevant laws and regulations, ensuring effective decision-making and compliance[117]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[118]. - The company maintains independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[122]. - The company has established a complete and independent financial accounting system, ensuring independent financial decision-making[122]. - The company has not faced any penalties from regulatory bodies regarding internal control issues during the reporting period[121]. Employee and Management - The workforce increased from over 700 to approximately 1,000 employees, a growth of about 38%, with the recruitment of 9 PhDs in various fields[46]. - The total number of employees at the end of the reporting period was 989, with 384 in the parent company and 605 in major subsidiaries[165]. - The company has established a comprehensive training system to enhance employee skills and capabilities, aligning with business needs[168]. - The company has implemented a differentiated compensation policy based on department and job nature, aiming for performance-oriented salary management[167]. Financial Management - The company raised a total of CNY 343 million through the issuance of 33.45 million shares, aimed at enhancing CDMO platform construction and clinical research service capabilities[38]. - The company reported a credit impairment loss of -5,309,692.89, which accounted for -11.28% of total profit, primarily due to bad debt losses[84]. - The company has established measures to ensure the fulfillment of immediate return commitments, with legal responsibilities for any violations[200]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares and a capital reserve increase of 4 shares per 10 shares to all shareholders[6]. - The cash dividend amount for the year was CNY 5,229,363.30, representing 100% of the total profit distribution[170]. - The company plans to issue 4 new shares for every 10 shares held as part of its capital reserve conversion plan[169].

博济医药科技股份有限公司 2021 年第三季度报告 □ 是 √ 否 证券代码：300404 证券简称：博济医药 公告编号：2021-085 博济医药科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 94,026,593.42 | 40.47% | 214,793,258.50 | 21.36% ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[14]. - The net profit attributable to shareholders for the first half of 2021 was RMB 50 million, an increase of 20% year-on-year[14]. - The management has set a revenue target of RMB 600 million for the full year 2021, reflecting a growth rate of 20%[14]. - The company achieved total operating revenue of 120,766,665.08 CNY, an increase of 9.74% compared to the same period last year[34]. - Net profit attributable to shareholders was 14,077,398.68 CNY, representing an 18.55% increase year-over-year[34]. - The company reported a total comprehensive income of CNY 16,444,393.82 for the first half of 2021, compared to CNY 15,080,552.18 in the same period of 2020[180]. - The company reported a net profit for the first half of 2021 of CNY 10,481,013.74, a decrease of 15.7% compared to CNY 12,432,465.60 in the same period of 2020[183]. - The company reported a total cash inflow from financing activities of CNY 368,760,838.34, compared to CNY 49,727,636.05 in the previous year, indicating a strong financing position[190]. Research and Development - The company plans to invest RMB 100 million in research and development for new drug technologies in the upcoming year[14]. - Research and development expenses rose by 14.95% to ¥12,342,227.62 from ¥10,737,338.09, reflecting ongoing investment in innovation[57]. - The company has developed a new drug, a fluconazole ear drop, which has received a patent certificate from the National Intellectual Property Administration[41]. - The company plans to continue its research and development efforts in new products and technologies[196]. - The company’s R&D expenditure for the first half of 2021 was approximately 5,000 million yuan, reflecting its commitment to innovation and product development[200]. Market Expansion and Strategy - User data indicates a growth in the customer base by 25%, reaching a total of 10,000 active users by the end of June 2021[14]. - The company has expanded its market presence by entering two new provinces, increasing its operational footprint by 30%[14]. - The company is actively pursuing partnerships with international firms to leverage new technologies and expand its research capabilities[14]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[170]. - The company aims to expand its market presence through strategic partnerships and potential acquisitions in the healthcare sector[200]. Financial Health and Investments - Total assets at the end of the reporting period were 1,088,411,313.70 CNY, a 45.19% increase from the end of the previous year[34]. - The net assets attributable to shareholders reached 776,596,497.02 CNY, up 74.81% from the previous year[34]. - The company reported a significant increase in cash flow, with cash and cash equivalents nearly tripling compared to the previous period[170]. - The company has committed to invest 10,681.59 million yuan in the CDMO platform construction project, with no funds utilized to date[76]. - The company plans to continue its investment strategy, focusing on expanding its market presence and enhancing product development capabilities[190]. Risks and Challenges - The company faces risks related to contract execution in new drug development, including potential delays and terminations due to unmet research expectations and changes in client direction[89]. - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[90]. - New business expansions into preclinical research and CDMO services may face challenges due to existing competitive companies and the company's limited experience in these areas[91]. Shareholder and Equity Information - The company has not distributed cash dividends for the current fiscal year, focusing instead on reinvestment[4]. - The company’s stock option incentive plan allowed for the exercise of 1,252,290 shares during the second exercise period, impacting earnings per share and net assets per share[144]. - The largest shareholder, Wang Tingchun, holds 30.85% of the shares, amounting to 80,618,642 shares, with 20,154,661 shares pledged[153]. - The company has a total of 17,767 ordinary shareholders as of the end of the reporting period[153]. - The company’s major shareholders have a total of 60,463,981 shares under lock-up, with a release schedule of 25% annually[145]. Legal and Compliance - The company reported a lawsuit involving its wholly-owned subsidiary with a claim amount of 2.5995 million yuan, currently in the second instance stage, which is not expected to significantly impact operations[113]. - The company has not faced any significant environmental issues or administrative penalties during the reporting period[103]. - The financial report for the first half of 2021 was not audited, indicating a potential area of concern for investors[167].

Financial Performance - The company's revenue for Q1 2021 was ¥55,245,275.36, representing a 165.36% increase compared to ¥20,818,697.66 in the same period last year[8] - Net profit attributable to shareholders was ¥7,369,156.02, a significant turnaround from a loss of ¥5,863,094.83, marking a 225.69% increase[8] - The net profit after deducting non-recurring gains and losses was ¥2,880,893.96, compared to a loss of ¥7,519,974.54, reflecting a 138.31% improvement[8] - Basic earnings per share were ¥0.0325, up 225.00% from -¥0.0260 in the same quarter last year[8] - The company reported a total sales revenue of 12,518,428.88 yuan, accounting for 22.67% of its total operating income[26] - The total operating revenue for the first quarter reached CNY 55,245,275.36, a significant increase from CNY 20,818,697.66 in the previous period[47] - The net profit for the first quarter reached CNY 9,899,292.90, a turnaround from a net loss of CNY 5,698,021.32 in the same period last year[49] - The company's operating profit was CNY 11,126,644.32, compared to an operating loss of CNY 7,242,531.16 in the previous year[49] - The total comprehensive income for the quarter was CNY 10,081,451.44, compared to a loss of CNY 5,485,594.15 in the previous year[50] Cash Flow - The net cash flow from operating activities reached ¥7,490,830.80, a substantial increase of 1,514.39% from -¥529,616.16 in the previous year[8] - The cash inflow from operating activities amounted to CNY 70,467,706.01, an increase from CNY 44,149,562.53 in the previous period, representing a growth of approximately 59.5%[56] - The net cash flow from operating activities was CNY 7,490,830.80, recovering from a negative CNY 529,616.16 in the prior period[57] - The total cash outflow from investing activities was CNY 69,796,489.65, significantly higher than CNY 9,946,990.39 in the previous period, leading to a net cash flow from investing activities of -CNY 11,440,909.02[57] - Cash inflow from financing activities totaled CNY 16,480,000.00, down from CNY 20,115,000.00 in the previous period, resulting in a net cash flow from financing activities of -CNY 5,097,434.12[58] - The ending balance of cash and cash equivalents was CNY 137,507,691.92, compared to CNY 80,808,720.47 at the end of the previous period, indicating a significant increase[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥759,934,380.33, an increase of 1.37% from ¥749,631,868.84 at the end of the previous year[8] - The total liabilities decreased slightly to CNY 263,630,226.54 from CNY 264,636,745.37, indicating a reduction of about 0.38%[41] - The company's equity attributable to shareholders reached CNY 452,929,084.80, up from CNY 444,239,449.04, reflecting an increase of about 1.56%[42] - The total non-current liabilities were CNY 18,723,076.22, with an adjustment of CNY 1,242,203.98 due to the new leasing standards[65] - The company reported a total of CNY 643,680,859.69 in total assets for the first quarter of 2021[68] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,132[12] - The largest shareholder, Wang Tingchun, holds 35.57% of the shares, with 60,463,981 shares pledged[12] - Net assets attributable to shareholders increased by 1.96% to ¥452,929,084.80 from ¥444,239,449.04 at the end of the last year[8] Business Operations - The company signed new contracts worth approximately ¥100 million during the reporting period, reflecting a year-on-year growth of about 146%[21] - The company is actively adjusting its business structure in response to potential policy changes in the pharmaceutical industry to mitigate risks[25] - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[29] - The company has signed contracts that allow for additional service fees under certain conditions to mitigate risks associated with budget overruns[27] Research and Development - Research and development expenses rose to ¥6,513,359.61, a 32.91% increase, as the company intensified its R&D investments[18] - The company reported a significant increase in other income, totaling ¥5,646,067.64, which is a 174.97% increase due to government subsidies related to daily activities[18] Risk Management - The company is facing risks related to contract execution, including potential delays and terminations due to clinical research failures or changes in client research directions[26] - The company has established a specific responsibility assumption model for project delays to manage risks effectively[28] - The company is enhancing its internal management and operational efficiency to address risks associated with its expanding business scale[29] - The company experienced a credit impairment loss of CNY 1,526,077.90, compared to a reversal of CNY -1,034,789.10 in the previous year, indicating potential credit risk issues[48] Compliance and Standards - The company has not reported any violations regarding external guarantees during the reporting period[34] - The company has implemented the new leasing standards effective January 1, 2021, impacting the financial statements[69] - The first quarter report for 2021 was not audited[70]